Document Detail


Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
MedLine Citation:
PMID:  18374881     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Increased oxidative stress, a common feature in chronic heart failure, has been associated with inflammation, endothelial dysfunction, and extracellular matrix degradation. Statins have known anti-inflammatory and anti-oxidant effects; however, their role in chronic heart failure is still controversial. METHODS: This was a prospective study of 38 patients with stable systolic chronic heart failure. Patients received a 4-week placebo course, followed by atorvastatin 20 mg/day for 8 weeks. Oxidative stress, inflammation and remodeling markers, brachial artery flow-mediated vasodilation, and 6-minute walk test were evaluated at baseline, 4, and 8 weeks. RESULTS: Mean age was 58 +/- 12. Mean left ventricular ejection fraction was 27% +/- 12%. No significant differences were observed between measurements at baseline and after placebo. Atorvastatin induced a significant decrease of matrix metalloproteinase-9 activity, high-sensitivity C-reactive protein, tumor necrosis factor-alpha, interleukin-6, and malondialdehyde, and a significant increase of endothelial superoxide dismutase activity when compared with placebo. No differences in tissue inhibitor of matrix metalloproteinase and matrix metalloproteinase-2 activities were observed. Atorvastatin use was associated with an improved flow-dependent brachial vasodilation and exercise capacity in the 6-minute walk test. CONCLUSIONS: In chronic heart failure patients, atorvastatin therapy is associated with a decrease of inflammation and extracellular matrix remodeling, improving both endothelial function and exercise capacity.
Authors:
Pablo F Castro; Rodrigo Miranda; Hugo E Verdejo; Douglas Greig; Luigi A Gabrielli; Hernán Alcaino; Mario Chiong; Carlos Bustos; Lorena Garcia; Rosemarie Mellado; José Luis Vukasovic; Ivan Godoy; Sergio Lavandero
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation     Volume:  27     ISSN:  1557-3117     ISO Abbreviation:  J. Heart Lung Transplant.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-31     Completed Date:  2008-04-29     Revised Date:  2009-04-16    
Medline Journal Info:
Nlm Unique ID:  9102703     Medline TA:  J Heart Lung Transplant     Country:  United States    
Other Details:
Languages:  eng     Pagination:  435-41     Citation Subset:  IM    
Affiliation:
Departamento de Enfermedades Cardiovasculares, Hospital Clínico, Pontificia Universidad Católica de Chile, Santiago, Chile. pcastro@med.puc.cl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Biological Markers / metabolism
Brachial Artery / drug effects,  physiopathology
Chronic Disease
Endothelium, Vascular / drug effects*,  physiopathology
Exercise Tolerance*
Female
Heart Failure / drug therapy*,  physiopathology
Heptanoic Acids / adverse effects,  therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  therapeutic use*
Inflammation / metabolism,  prevention & control*
Male
Middle Aged
Oxidative Stress*
Prospective Studies
Pyrroles / adverse effects,  therapeutic use*
Time Factors
Vasodilation
Walking
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin
Comments/Corrections
Comment In:
J Heart Lung Transplant. 2009 Jan;28(1):114-5   [PMID:  19134543 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sex-specific predictive power of 6-minute walk test in chronic heart failure is not enhanced using p...
Next Document:  Decreased myocardial chromogranin a expression and colocalization with brain natriuretic peptide dur...